Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G
- Development stage
- Unknown
- Lead developer
- Japan Kyowa Industrial
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G (JK-5G) is an orally administered postbiotic microecological preparation containing over 21 inactivated strains of Lactobacillus and their metabolic products. Developed by Japan Kyowa Industrial and investigated by clinical institutions including the First Affiliated Hospital of Wenzhou Medical University and Chongqing University Cancer Hospital, JK-5G is designed to modulate the gut-microbiome-immune axis. It is being evaluated in clinical trials for promoting postoperative gastrointestinal function recovery after surgery for malignant mechanical bowel obstruction, as well as for alleviating cancer-related pain and reducing immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors.
- Other names
- JK-5G postbioticsJK5G postbioticsJK 5G postbioticsJK5G microecological formulationJK-5G microecological formulationJK 5G microecological formulationJK5G microecological preparationJK-5G microecological preparationJK 5G microecological preparation
02
Targets
AHR (Aryl hydrocarbon receptor)FFAR2FFAR3 (Free fatty acid receptor 3)NOD1 (Nucleotide-binding oligomerization domain-containing protein 1)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G.